Loading...
NPI 1689679441 · Memphis, TN · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Tawan Khamapirad is a ophthalmology physician provider located in Memphis, Tennessee. This profile covers 19 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Tawan Khamapirad |
| Address | 6005 Park Ave |
| City | Memphis |
| State | TN |
| ZIP | 38119 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 17, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.4M |
| Medicaid | $4.2K |
This provider is effectively Medicare-dominant: lifetime Medicare revenue is $3.4M versus total Medicaid revenue of $4.2K, indicating Medicare drives virtually all billed revenue and the practice is not materially reliant on Medicaid volume. The Medicaid footprint is tiny in absolute dollars despite having procedure counts on file.
Medicare revenue is highly concentrated: the precomputed top 3 Medicare codes account for 76.7% of this provider's total Medicare revenue, with J0178 alone representing $1.8M (51.9% of Medicare revenue). The top three contributors are J0178, Q5128 ($464.6K, 13.6%), and J2777 ($381.1K, 11.2%), signaling that a small set of intravitreal drug administrations produces most Medicare revenue.
The procedure and imaging mix point to a retina-focused ophthalmology practice operating a high-volume injection clinic: high-revenue drug codes J0178, Q5128, and J2777 are front-line anti-VEGF/faricimab therapy administrations, and the procedure code 67028 has 3.2K claims and $283.4K revenue, consistent with dedicated intravitreal injection sessions. Frequent retinal imaging is also present — 92134 has 3.9K claims and $111.8K — supporting ongoing management of chronic retinal disease such as AMD or diabetic macular edema.
Competitive standing across Medicare codes is mixed: the provider is an extreme outlier on retinal imaging with 92134 ranking #156 of 26868 providers nationally (99th percentile; extreme outlier, far above typical national volume) and is notably above typical volume on the intravitreal procedure 67028 (rank #77 of 4255, 98th percentile). At the same time J0178, which drives the largest share of revenue, ranks #299 of 3204 providers nationally (91th percentile; typical, unremarkable volume for this code), indicating high local revenue impact without corresponding top-tier national dominance for that specific drug code.
Medicaid activity is concentrated and low-dollar: the precomputed top 3 Medicaid codes account for 100.0% of Medicaid revenue, with 67028 contributing $3K (65.5%), 92134 $1.2K (26.3%), and J9035 $380 (8.2%). Medicaid payments per claim are very low in absolute terms (e.g., 67028 Medicaid avg paid/claim $4 and 92134 $1) and in-state rank percentiles (67028 #19 of 37, 50th percentile; 92134 #25 of 81, 70th percentile) indicate a modest statewide presence rather than dominance.
There is clear operational reliance on high-volume injection workflows: claims volume includes 2.6K claims for J0178 and 3.2K claims for 67028 on Medicare, plus 2.2K claims for Q5128 and 13.1K claims for J2777, signaling repeated, clinic-based administration of intravitreal agents rather than infrequent surgical procedures. This pattern implies scheduling, staffing, and supply-chain priorities around frequent eye injections and routine imaging.
The practice shows some additional notable Medicare-level strengths beyond injections: J9035 (bevacizumab) ranks #19 of 1852 providers nationally (99th percentile; notably above typical national volume) and 92014 (comprehensive established eye exam) ranks in the 98th percentile by provider count, reflecting a steady outpatient follow-up and management practice that complements the injection/imaging activity. These high percentiles on adjunct codes reinforce a care model centered on continual monitoring and treatment of retinal disease.
Provider tenure is long-standing: the NPI was enumerated on 2005-06-17 (~21 years ago), indicating an established practice history which may help explain the accumulation of high-volume injection and imaging workflows and the concentrated payer revenue profile over time.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,560 | $690 | $1.8M |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 2,170 | $210 | $464.6K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 13,140 | $30 | $381.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 3,220 | $90 | $283.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,860 | $30 | $111.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,310 | $80 | $105.9K |
| J9035 | Injection, bevacizumab, 10 mg | 1,980 | $50 | $105.2K |
| J2778 | Injection, ranibizumab, 0.1 mg | 310 | $180 | $56K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 250 | $160 | $38.7K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 30 | $840 | $22.7K |
Showing 1–10 of 19
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
19 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 6 | 80 | 790 | $680 | $769.8K |
| J2777 | 31 | 50 | 15,060 | $30 | $592.1K |
| Q5128 | 7 | 20 | 1,190 | $210 | $394K |
| J2778 | 39 | 40 | 1,340 | $180 | $370.2K |
| 67028 | 1 | 80 | 1,130 | $90 | $98.5K |
| J7312 | 6 | 10 | 210 | $150 | $45.8K |
| 67042 | 16 | 40 | 20 | $1,020 | $34.5K |
| 92014 | 15 | 810 | 120 | $80 | $19.2K |
| J9035 | 2 | 70 | 140 | $50 | $17.1K |
| 99214 | 9,672 | 11,370 | 120 | $80 | $16.6K |
Showing 1–10 of 19
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 760 | $1 | $3K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,210 | $1 | $1.2K |
| J9035 | Injection, bevacizumab, 10 mg | 380 | $1 | $380 |
How this provider's Medicaid billing volume and revenue compare to other Tennessee providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Tennessee median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 19 | 40 | 760 | $50 | $193K |
| J9035 | Injection, bevacizumab, 10 mg | 19 | 30 | 780 | $20 | $65.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 25 | 80 | 440 | $10 | $29.6K |
Other providers in the same ZIP code as Tawan Khamapirad, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.